ThermoGenesis (KOOL) will merge with privately held TotipotentRx, a cell-based regenerative medicine company. KOOL will issue 12.491M shares worth some $18.6M to TotipotentRx. The deal is expected to close in Q4 and will be "transformative," in the words of KOOL CEO Matthew Plavan. (PR)
ThermoGenesis (KOOL) will merge with privately held TotipotentRx, a cell-based regenerative...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs